Give me information about weekly diabetes mellitus injection

Reading File

Finding Sources

Searching PubMed

weekly injectable diabetes semaglutide insulin icodec

Searching the Web

weekly diabetes injection drugs 2025 GLP-1 insulin icodec semaglutide tirzepatide

Reading File

Finding Sources

Searching PubMed

GLP-1 receptor agonist type 2 diabetes weekly injection efficacy

Reading Article

PMID: 41574970

Finding Sources

Reading File

Finding Sources

Reading File

Here is a thorough overview of weekly injectable agents used in diabetes mellitus management, drawing from Harrison's Principles of Internal Medicine (22nd Ed., 2025), Katzung's Pharmacology (16th Ed.), Fuster and Hurst's The Heart (15th Ed.), and a 2026 systematic review/meta-analysis.

Weekly Injections for Diabetes Mellitus

There are two main categories of once-weekly injectable drugs used in diabetes: GLP-1 receptor agonists (and the dual GIP/GLP-1 agonist tirzepatide) and once-weekly basal insulins (primarily insulin icodec).

1. GLP-1 Receptor Agonists (Once-Weekly)

Semaglutide (Ozempic / Wegovy)

Mechanism: Synthetic analog of human GLP-1 that is resistant to degradation by DPP-4. It stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite centrally.

Pharmacokinetics: Half-life of ~7 days, allowing once-weekly subcutaneous (SC) dosing. Albumin binding contributes to its long duration of action.

Dosing (Type 2 Diabetes - Ozempic):

Start: 0.25 mg SC weekly for 4 weeks (tolerability dose)
Then: 0.5 mg weekly for 4 weeks
Maintenance: 1.0 mg weekly; can escalate to 2.0 mg weekly if needed

Dosing (Obesity/Weight Management - Wegovy):

Escalate gradually every 4 weeks: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly

Glycemic Efficacy: HbA1c reduction of ~1.1-1.6% in clinical trials (SUSTAIN program).

Cardiovascular Outcomes (SUSTAIN-6 trial): In 3,297 patients with T2D and high CV risk, semaglutide reduced 3-point MACE by 26% (HR 0.74, 95% CI 0.58-0.95) vs. placebo, driven mainly by reduced non-fatal stroke. - Fuster and Hurst's The Heart, 15th Ed.

SELECT Trial (2024): In patients with cardiovascular disease, overweight/obesity but without diabetes, semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by 20% vs. placebo. - Harrison's Principles of Internal Medicine 22E

Weight Loss (STEP Program):

STEP 1-4: placebo-subtracted weight loss of 6.2-14.8% at 68 weeks
STEP 5: 12.6% weight loss at 104 weeks
STEP TEENS (adolescents): 16.1% reduction in BMI vs. +0.6% for placebo

FDA Approval Timeline:

T2D (Ozempic): 2017 (up to 1.0 mg); 2022 (up to 2.0 mg)
Chronic weight management (Wegovy): 2021 (adults), 2022 (adolescents)
MASH (August 2025): First GLP-1 approved for metabolic steatohepatitis

Dulaglutide (Trulicity)

Mechanism: GLP-1 receptor agonist fused to an IgG4-Fc fragment, enabling once-weekly dosing.

Cardiovascular Outcomes (REWIND trial): In 9,901 patients over 5.4 years, dulaglutide reduced 3-point MACE by 12% (HR 0.88, 95% CI 0.79-0.99), notably enrolling patients with lower CV risk (only 32% had prior CVD). - Fuster and Hurst's The Heart, 15th Ed.

Exenatide Extended-Release (Bydureon)

Once-weekly formulation of exenatide (the original GLP-1 agonist).

Cardiovascular Outcomes (EXSCEL trial): HR 0.91 (95% CI 0.83-1.00) for MACE - non-inferior to placebo but not superior. - Fuster and Hurst's The Heart, 15th Ed.

2. Dual GIP/GLP-1 Receptor Agonist (Once-Weekly)

Tirzepatide (Mounjaro / Zepbound)

Mechanism: First-in-class dual agonist at both the GIP receptor and GLP-1 receptor. It is an analog of native GIP with albumin-binding fatty acid modification giving a half-life of ~117 hours, supporting once-weekly dosing. GIP receptor activation in the brain acts synergistically with GLP-1 receptor activation to produce greater weight loss than GLP-1 alone.

Dosing:

Start: 2.5 mg SC weekly for 4 weeks
Increase by 2.5 mg increments every 4 weeks
Maximum: 15 mg SC weekly

Glycemic Efficacy: HbA1c reduction of 1.9-2.6% (dose-dependent) vs. comparators. Average weight loss of 6.2-12.9 kg in diabetes trials.

Weight Loss (SURMOUNT Program):

Placebo-subtracted weight loss at 15 mg dose: 11.6-21.4% (depending on population)

SURPASS-2 Trial: Tirzepatide was superior to once-weekly semaglutide 1.0 mg for both HbA1c reduction and weight loss at all doses.

FDA Approval:

T2D (Mounjaro): 2022
Chronic weight management (Zepbound): 2023
Katzung's Basic and Clinical Pharmacology, 16th Ed., Harrison's Principles of Internal Medicine 22E

3. Once-Weekly Basal Insulin (Insulin Icodec)

Mechanism: A long-acting insulin analog modified with three amino acid substitutions and a fatty diacid moiety enabling strong, reversible albumin binding. This dramatically extends the half-life to ~196 hours (~8 days), achieving steady-state within 3-4 weeks of once-weekly dosing.

Glycemic Efficacy (2026 Meta-Analysis - Bourron & Denimal, Diabetes Obes Metab):

16 RCTs (including 5 major trials published in 2025) showed OW insulins reduced HbA1c 0.12% more than once-daily insulin (pooled mean difference: -0.12%, 95% CI -0.19 to -0.04, p=0.007)
Time-in-range (TIR) was significantly longer (+2.41% of total time, p=0.002)
Fasting plasma glucose: comparable to daily insulin
Hypoglycemia: no increase in clinically significant or severe hypoglycemia (pooled IRR 1.04, p=0.75)
Body weight: modest gain (+0.33 kg) when trials using IcoSema combination excluded

IcoSema (Combination): A fixed-ratio combination of insulin icodec + semaglutide (once-weekly) is in clinical development. COMBINE trials showed IcoSema was superior to insulin icodec alone (COMBINE 1), superior to semaglutide alone (COMBINE 2), and non-inferior to basal-bolus therapy (COMBINE 3).

Approval: Approved for T2D in multiple countries (including Type 1 diabetes in some jurisdictions as of 2025 per Diabetes Care journal).

Bourron & Denimal (2026), Diabetes Obes Metab, PMID 41574970 - systematic review/meta-analysis of 16 RCTs on once-weekly insulins

Comparison Summary Table

Drug	Class	Dosing	HbA1c Reduction	Weight Effect	CV Benefit
Semaglutide (Ozempic)	GLP-1 RA	0.5-2.0 mg weekly SC	~1.1-1.6%	-3 to -6 kg	Yes (SUSTAIN-6)
Semaglutide (Wegovy)	GLP-1 RA	up to 2.4 mg weekly SC	-	-12-15% body weight	Yes (SELECT)
Dulaglutide (Trulicity)	GLP-1 RA	0.75-1.5 mg weekly SC	~1.1-1.4%	Modest loss	Yes (REWIND)
Exenatide ER (Bydureon)	GLP-1 RA	2 mg weekly SC	~1.0-1.2%	Modest loss	Non-inferior
Tirzepatide (Mounjaro)	GIP/GLP-1 dual agonist	2.5-15 mg weekly SC	~1.9-2.6%	-6 to -13 kg (T2D); up to -21% (obesity)	Trials ongoing
Insulin icodec	Basal insulin	Once weekly SC	Modest improvement vs daily insulin	+0.33 kg	No specific CV data

Shared Side Effects and Contraindications

Common adverse effects (all GLP-1 based agents):

Nausea, vomiting, diarrhea, constipation (most common; usually mild and transient, worse at higher doses and during dose escalation)
Injection site reactions
Risk of pancreatitis (counsel patients to seek care for unexplained severe abdominal pain)

Contraindications:

Personal or family history of medullary thyroid carcinoma or MEN type 2 (all GLP-1 RAs and tirzepatide - due to thyroidal C-cell tumors observed in rodents)
Caution with renal impairment (exenatide-related acute renal injury reports, often with dehydration)

Why Once-Weekly? Clinical Rationale

Once-weekly agents reduce injection burden significantly compared to daily or multiple-daily injections. This improves patient adherence and quality of life, a key advantage in the management of a chronic condition like diabetes mellitus. The 2026 meta-analysis by Bourron & Denimal confirms that once-weekly insulins achieve modestly better HbA1c reduction and improved time-in-range without increasing hypoglycemia - supporting their favorable benefit-risk profile.

What about icodec

Finding Sources

Searching PubMed

insulin icodec once weekly type 2 diabetes

Searching the Web

insulin icodec awiqli FDA approval dosing mechanism ONWARDS trials 2024 2025

Reading Article

PMID: 37356066

Reading Article

PMID: 37354562

Reading Article

PMID: 37863084

Reading Web Page

https://www.hcplive.com/view/fda-approves-awiqli-insulin-ico…

Insulin Icodec (Awiqli) - Complete Overview

What Is It?

Insulin icodec (brand name Awiqli) is the world's first and only once-weekly basal insulin, developed by Novo Nordisk. It was FDA-approved on March 26, 2026 for adults with type 2 diabetes - reducing injections from 365 per year to just 52. It is also approved in the EU and 13+ other countries.

Note: The FDA approval is limited to type 2 diabetes only. A May 2024 FDA advisory committee voted 7-4 against recommending it for type 1 diabetes due to hypoglycemia concerns, and the T1D indication remains under regulatory review.

Mechanism and Pharmacokinetics

Insulin icodec is a modified human insulin analog with three key structural changes that dramatically extend its duration of action:

Three amino acid substitutions that reduce insulin receptor binding affinity slightly, slowing its clearance
Fatty diacid side chain attached via a linker, enabling strong and reversible albumin binding in the bloodstream
These modifications result in a half-life of ~196 hours (~8 days), vs. ~25 hours for insulin degludec

Because of this prolonged half-life, a single SC injection covers basal insulin requirements for an entire week. Steady-state is reached within 3-4 weeks of weekly dosing.

Dosing and Administration

Formulation: 700 units/mL (U-700) - higher concentration than standard insulins
Device: Administered via the Awiqli FlexTouch pen (subcutaneous injection)
Schedule: Once weekly, on the same day each week
Starting dose (insulin-naive T2D): Typically 70% of what would be used as a daily basal dose, given weekly
Titration: Dose adjusted based on fasting glucose targets
Not approved for children/adolescents (pediatric safety/efficacy not established)
When switching from daily basal insulin, a loading dose approach may be used in the first week to reach therapeutic levels faster

The ONWARDS Clinical Trial Program

Six Phase 3a trials evaluated insulin icodec across diverse T2D and T1D populations. The FDA approval is based on 4 of the T2D trials (approx. 2,680 adults).

Trial	Population	Comparator	Key Result
ONWARDS 1 (N Engl J Med, 2023)	Insulin-naive T2D, 78 weeks	Glargine U100 once-daily	HbA1c: -1.55% (icodec) vs -1.35% (glargine); superior (p=0.02). Time-in-range: 71.9% vs 66.9% (+4.27 pp)
ONWARDS 3 (JAMA, 2023)	Insulin-naive T2D + oral agents, 26 weeks	Degludec once-daily	HbA1c: -1.57% vs -1.36%; superior (p=0.002)
ONWARDS 4 (Lancet, 2023)	T2D on basal-bolus, 26 weeks	Glargine U100	HbA1c: -1.16% vs -1.18%; non-inferior
ONWARDS 5 (Ann Intern Med, 2023)	Insulin-naive T2D, app-guided titration, 52 weeks	Daily basal analogues	HbA1c: -1.68% vs -1.31%; largest separation in program
ONWARDS 6 (Lancet, 2023)	Type 1 diabetes, 52 weeks	Degludec once-daily	HbA1c change: non-inferior (0.05 pp ETD), but hypoglycemia rate was significantly higher (19.9 vs 10.4 events/patient-year, rate ratio 1.9)

Meta-analysis across 5 ONWARDS RCTs (3,764 participants):

Incremental HbA1c reduction: -0.17% vs daily basal insulin (95% CI -0.28 to -0.06, p=0.003)
More patients achieved HbA1c <7%: OR 1.51 (95% CI 1.14-1.99, p=0.004)
Rosenstock et al., N Engl J Med 2023 PMID 37356066
Lingvay et al., JAMA 2023 PMID 37354562
Russell-Jones et al., Lancet 2023 PMID 37863084

Safety Profile

Hypoglycemia - the key concern:

In insulin-naive T2D (ONWARDS 1): combined clinically significant or severe hypoglycemia rate was 1.64x higher with icodec vs glargine U100 (0.30 vs 0.16 events/person-year)
In T1D (ONWARDS 6): hypoglycemia rate was 1.9x higher vs degludec - this was the primary reason for the FDA's hesitation on the T1D indication
In T2D with basal-bolus (ONWARDS 4): hypoglycemia was comparable

Why more hypoglycemia? The very long half-life (~8 days) means that if hypoglycemia occurs, it is harder to "correct" quickly because the insulin level cannot be rapidly reduced. Any dose adjustment takes ~2-3 weeks to fully reflect in circulating levels.

Other adverse effects (common in ONWARDS trials):

Hypoglycemia
Injection site reactions
Lipodystrophy (skin thickening or pits at injection site)
Weight gain
Pruritus, rash
Peripheral edema

Contraindications/cautions:

Hypersensitivity to insulin icodec or any excipient
Not for pediatric use
Requires careful titration; do not adjust dose more frequently than every 3-4 days due to the long half-life

IcoSema: The Next Step

A fixed-ratio combination of insulin icodec + semaglutide (both once-weekly) called IcoSema is in late-stage development:

COMBINE 1 (Lancet Diabetes Endocrinol, July 2025): IcoSema was superior to icodec alone in HbA1c reduction
COMBINE 2 (Diabetologia, April 2025): IcoSema was superior to semaglutide alone
COMBINE 3 (Lancet Diabetes Endocrinol, July 2025): IcoSema was non-inferior to basal-bolus multiple daily injections - a single weekly injection matching a complex daily regimen

This combination would allow patients to manage both basal insulin needs AND GLP-1 benefits with a single injection per week.

Why It Matters Clinically

Comparison	Daily Basal Insulin	Insulin Icodec
Injection frequency	365/year	52/year
HbA1c reduction	~1.35-1.36%	~1.55-1.68%
Time in range	~66-67%	~71-72%
Hypoglycemia risk (T2D naive)	Lower	Slightly higher
Adherence advantage	Baseline	Significant improvement

The ADA Standards of Care in Diabetes 2026 now recognizes once-weekly icodec as an alternative to daily basal insulin in adults with T2D. It is particularly suited to patients who struggle with daily injection adherence or those newly starting basal insulin therapy.

This is a shared conversation. Sign in to Orris to start your own chat.